McDavid Stilwell
Plus aucun poste en cours
Fortune : 179 979 $ au 31/03/2024
Profil
McDavid Stilwell worked as a Director of Business Development & Communications at GTx, Inc. from 2005 to 2012.
He then worked as the SVP of Corporate Communications & Investor Relations at Sangamo Therapeutics, Inc. After that, he worked as the VP of Communications & Business Development at Orexigen Therapeutics, Inc. from 2012 to 2016.
Currently, he is the Chief Financial Officer at Coherus BioSciences, Inc. starting from 2021 and ending in 2023.
Mr. Stilwell completed his undergraduate degree from St. John's College in 1993 and earned an MBA from Harvard Business School in 2005.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2023 | 75 305 ( 0,07% ) | 179 979 $ | 31/03/2024 |
Anciens postes connus de McDavid Stilwell
| Sociétés | Poste | Fin |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Director of Finance/CFO | 08/12/2023 |
| OREXIGEN THERAPEUTICS, INC. | Investor Relations Contact | 01/11/2016 |
GTx, Inc.
 GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | Public Communications Contact | 01/01/2012 |
| SANGAMO THERAPEUTICS, INC. | Investor Relations Contact | - |
Formation de McDavid Stilwell
| Harvard Business School | Masters Business Admin |
| St. John's College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
